Azzad Asset Management Inc. ADV Has $543,000 Position in Repligen Corporation $RGEN

Azzad Asset Management Inc. ADV cut its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 59.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,314 shares of the biotechnology company’s stock after selling 4,869 shares during the quarter. Azzad Asset Management Inc. ADV’s holdings in Repligen were worth $543,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of RGEN. Measured Wealth Private Client Group LLC acquired a new position in Repligen during the 3rd quarter worth about $29,000. CWM LLC lifted its holdings in Repligen by 67.2% during the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock worth $45,000 after buying an additional 135 shares during the period. Johnson Financial Group Inc. acquired a new position in Repligen during the 3rd quarter worth about $65,000. Trust Co. of Vermont acquired a new position in Repligen during the 3rd quarter worth about $67,000. Finally, Wilmington Savings Fund Society FSB lifted its holdings in Repligen by 2,750.0% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock worth $69,000 after buying an additional 495 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. UBS Group cut their target price on Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Wednesday, February 25th. Wells Fargo & Company cut their target price on Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. KeyCorp reissued an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. HC Wainwright boosted their price objective on Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, March 23rd. Finally, Wall Street Zen downgraded Repligen from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $176.92.

Repligen Stock Up 3.9%

Shares of NASDAQ:RGEN opened at $119.77 on Thursday. The company has a market capitalization of $6.75 billion, a price-to-earnings ratio of 140.91, a P/E/G ratio of 2.30 and a beta of 1.19. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.37 and a quick ratio of 7.12. The business’s 50-day moving average is $127.67 and its 200-day moving average is $146.36. Repligen Corporation has a 1 year low of $105.06 and a 1 year high of $175.77.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The company had revenue of $197.91 million for the quarter, compared to the consensus estimate of $192.23 million. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The firm’s revenue was up 18.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.44 EPS. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Equities research analysts predict that Repligen Corporation will post 1.72 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.